(:ARQL)
Business Focus: N/A
Dec 30, 2019 02:59 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – INST, THOR, TCBI, ARQL
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Instructure, Inc. (NYSE: INST)The investigation concerns whether Instructure and its board of directors violated the federal securities laws...
Dec 28, 2019 02:00 pm ET
THOR, ARQL, TIF, and AMTD SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
Rigrodsky & Long, P.A. announces that it is investigating: Synthorx, Inc. (NASDAQ GS: THOR) regarding possible breaches of fiduciary duties and other violations of law related to Synthorx’s agreement to be acquired by Sanofi. Shareholders of...
Dec 23, 2019 09:00 am ET
LOGM, ARQL, TIF, and BOLD SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
Rigrodsky & Long, P.A. announces that it is investigating: LogMeIn, Inc. (NASDAQ GS: LOGM) regarding possible breaches of fiduciary duties and other violations of law related to LogMeIn’s agreement to be acquired by affiliates of Francisco...
Dec 16, 2019 08:00 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – ARQL, KEM, CBPX, TECD
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: ArQule, Inc. (NASDAQ: ARQL)The investigation concerns whether ArQule and its board of directors violated the federal securities laws and/or...
Dec 12, 2019 01:19 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of the Following Mergers
Rigrodsky & Long, P.A. announces that it is investigating: Progenics Pharmaceuticals, Inc. (NASDAQ GS: PGNX) regarding possible breaches of fiduciary duties and other violations of law related to Progenics’ agreement to be acquired by Lantheus...
Dec 09, 2019 11:59 am ET
ArQule Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of ArQule, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ARQL
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of ArQule, Inc. (NASDAQ: ARQL) to Merck for $20.00 per share is fair to ArQule shareholders. On behalf of ArQule shareholders, Halper Sadeh LLP may seek...
Dec 09, 2019 08:05 am ET
ArQule Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting
ArQule, Inc. (Nasdaq: ARQL) today announced final results from the phase 1 study for ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK) in patients with relapsed or refractory hematologic malignancies at the American Society of Hematology (ASH) 2019 Annual Meeting & Exposition in Orlando, Florida.
Dec 09, 2019 06:45 am ET
Merck to Acquire ArQule, Advancing Leadership in Oncology
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and ArQule, Inc. (Nasdaq: ARQL) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire ArQule for $20 per share in cash for an approximate total equity value of $2.7 billion. ArQule is a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. ArQule’s lead investigational candidate, ARQ 531, is a novel, oral Bruton’s tyrosine kinase (BTK) inhibitor cu
Nov 25, 2019 07:00 am ET
ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting
ArQule, Inc. (Nasdaq: ARQL) today announced that final clinical data from the company-sponsored phase 1 study of ARQ 531 will be presented on December 9, 2019 at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The poster presentation will highlight the final data set with respect to ARQ 531’s safety profile, clinical activity and durability across multiple refractory B-cell malignancies, including C481-mutant chronic lymphocytic leukemia (CLL).
Nov 13, 2019 07:00 am ET
ArQule to Participate in the Jefferies London Healthcare Conference on November 20, 2019
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2019 in London, UK.
Nov 06, 2019 09:05 am ET
ArQule Announces Release of American Society of Hematology Abstract Detailing Results of the Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologi
ArQule, Inc. (Nasdaq: ARQL) today announced the publication of the abstract highlighting data, as of July 19, 2019, from the phase 1 trial of ARQ 531, the company’s potent and reversible dual inhibitor of both wild type and C481-mutant Bruton’s tyrosine kinase (BTK), in patients with relapsed or refractory B-cell malignancies on the American Society of Hematology (ASH) website (
Oct 30, 2019 07:00 am ET
ArQule Reports Third Quarter 2019 Financial Results
ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2019.
Oct 29, 2019 04:01 pm ET
ArQule Presents Recent Data on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
ArQule, Inc. (Nasdaq: ARQL), today announced new clinical and preclinical data demonstrating the potential of the company’s AKT inhibitor ARQ 751 in treating solid tumors characterized by mutations in the PI3K/AKT/mTOR pathway. The findings were detailed in two poster presentations at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Oct 21, 2019 07:00 am ET
ArQule Announces Preclinical Data Demonstrating Potential of Miransertib (ARQ 092) to Treat PIK3CA-Driven Vascular Malformations at 2019 ASHG Annual Meeting
ArQule, Inc. (Nasdaq: ARQL), today announced preclinical data demonstrating the potential for miransertib (ARQ 092), it’s pan-AKT inhibitor, to treat PIK3CA driven vascular malformations (VMs) in a poster at the 2019 American Society of
Oct 16, 2019 07:00 am ET
ArQule Announces Presentations on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
ArQule, Inc. (Nasdaq: ARQL) today announced that it will be presenting data on the company’s AKT inhibitor, ARQ 751, in two poster presentations at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held from October 26th to October 30th, 2019 in Boston, Massachusetts.
Oct 16, 2019 07:00 am ET
ArQule to Report Third Quarter 2019 Financial Results on October 30, 2019
ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter of 2019 before the market opens on Wednesday, October 30, 2019. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business update.
Oct 08, 2019 07:00 am ET
ArQule to Present Preclinical Data on Miransertib for the Treatment of Vascular Malformations at the 2019 American Society of Human Genetics (ASHG) Annual Meeting
ArQule, Inc. (Nasdaq: ARQL) today announced that it will be presenting research on the company’s pan-AKT inhibitor, miransertib (ARQ 092), in a poster presentation at the 2019 ASHG Annual Meeting being held from October 15 to October 19, 2019 in Houston, Texas.
Oct 02, 2019 07:00 am ET
ArQule Announces First Patient Dosed in Registrational MOSIAC Trial of Miransertib for the Treatment of Proteus Syndrome and PIK3CA-related Overgrowth Spectrum
“After years of extensive preclinical and clinical efforts among ArQule and our collaborators, the MOSAIC trial represents an important milestone for patients with Proteus syndrome and PROS, their families and caregivers,” said Brian Schwartz, Chief Medical Officer of ArQule. “These patients currently have extremely limited therapeutic options and no approved or effective drug for their treatment. We are pleased that the FDA has granted miransertib Fast Track Designation for PROS and Rare Pediatric Disease Designation for Proteus syndrome.”
Sep 26, 2019 07:00 am ET
ArQule to Present at the 2019 Cantor Global Healthcare Conference on October 3, 2019
ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019 at 2:25 p.m. ET at the InterContinental New York Barclay in New York City.
Sep 17, 2019 07:00 am ET
ArQule to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies on September 24, 2019
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will participate in the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies on Tuesday, September 24, 2019 at The Parker New York Hotel in New York City.
Aug 28, 2019 07:00 am ET
ArQule to Participate in Citi’s 14th Annual Biotech Conference on September 4, 2019
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Marc Schegerin, Chief Financial Officer, will attend Citi’s investor conference on Wednesday, September 4, 2019 at the Four Seasons Hotel in Boston, MA.
Aug 07, 2019 07:00 am ET
ArQule Reports Second Quarter 2019 Financial Results
ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the second quarter of 2019.
Aug 05, 2019 07:00 am ET
ArQule to Participate in the BTIG Biotechnology Conference on Monday, August 12, 2019
ArQule, Inc. (Nasdaq:ARQL) today announced that Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will participate in the BTIG Biotechnology Conference on Monday, August 12, 2019 at The St. Regis New York in New York City.
Aug 01, 2019 07:00 am ET
ArQule to Present at the SVB Leerink Spotlight Series: Rare & Genetic Diseases on August 8, 2019
ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at the SVB Leerink Spotlight Series: Rare & Genetic Diseases on August 8, 2019 at 9:00 a.m. ET at the The Boston Harbor Hotel in Boston, MA.
Jul 24, 2019 07:00 am ET
ArQule to Report Second Quarter 2019 Financial Results on August 7, 2019
ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the second quarter of 2019 before the market opens on Wednesday, August 7, 2019. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business update.
Jun 27, 2019 01:09 pm ET
ArQule Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
ArQule, Inc. (Nasdaq: ARQL) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,387,500 shares at the public offering price of $9.75 per share. The exercise of the option to purchase additional shares brought the total number of shares of common stock sold by ArQule to 10,637,500 shares and increased the gross proceeds raised in the offering, before deducting underwriting discounts and commissions and estimated expenses of the offering payable by ArQu
Jun 25, 2019 07:00 am ET
ArQule Announces Pricing of $90 Million Public Offering of Common Stock
ArQule, Inc. (Nasdaq:ARQL) today announced the pricing of an underwritten public offering of 9,250,000 shares of its common stock at a price to the public of $9.75 per share. ArQule has granted the underwriters a 30-day option to purchase up to an additional 1,387,500 shares of its common stock. The offering is expected to close on or about June 27, 2019, subject to satisfaction of customary closing conditions. The gross proceeds to ArQule from the offering, excluding any exercise by the underwriters of their 30-day option to purchase additional shares, are expected to be approximately $90.2 m
Jun 24, 2019 04:37 pm ET
ArQule Announces Commencement of Proposed Public Offering of Common Stock
ArQule, Inc. (Nasdaq: ARQL) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In connection with the offering, ArQule expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. There can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares in the offering are to be sold by ArQule.
Jun 18, 2019 04:01 pm ET
ArQule to Present at the BMO Prescriptions for Success Healthcare Conference on June 25, 2019
ArQule, Inc. (Nasdaq: ARQL) today announced that Marc Schegerin, Chief
Financial Officer and Head of Strategy, will present at the BMO
Prescriptions for Success Healthcare Conference on June 25, 2019 at 8:00
a.m. ET at the The Mandarin Oriental New York, New York.
Jun 17, 2019 09:00 am ET
ArQule Announces Preliminary Results from Its Phase 1/2 Study of Miransertib (ARQ 092), in Patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an Oral Presentation at
ArQule, Inc. (Nasdaq:ARQL) today announced preliminary results from the
company’s phase 1/2 study of its pan-AKT inhibitor, miransertib (ARQ
092), in patients with PIK3CA-related Overgrowth Spectrum (PROS) and
Proteus syndrome (PS) in an oral presentation at the European Society of
Human Genetics Conference in Gothenburg, Sweden.
Jun 14, 2019 03:30 am ET
ArQule Announces Clinical Proof-of-Concept Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2019 EHA Annual Me
ArQule, Inc. (Nasdaq: ARQL) today announced preliminary results from the
Company’s phase 1 dose escalation study for ARQ 531, an orally
bioavailable, potent and reversible dual inhibitor of both wild type and
C481S-mutant Bruton’s tyrosine kinase (BTK) in patients with relapsed or
refractory hematologic malignancies at the 2019 European Hematology
Association (EHA) Annual Meeting in Amsterdam, the Netherlands.
Jun 10, 2019 07:00 am ET
ArQule Announces Oral Presentation for its Pan-AKT Inhibitor, Miransertib, at the 2019 European Society of Human Genetics (ESHG) Conference
ArQule, Inc. (Nasdaq:ARQL), today announced it will present preliminary
results from the company’s phase 1/2 study of its pan-AKT inhibitor,
miransertib (ARQ 092), in patients with PIK3CA-related Overgrowth
Spectrum (PROS) and Proteus syndrome (PS) in an oral presentation at the
European Society of Human Genetics Conference held from June 15-18, 2019
in Gothenburg, Sweden.
Jun 07, 2019 07:00 am ET
ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 24th Congress of the European Hematology Association (EHA)
ArQule, Inc. (Nasdaq: ARQL), today announced that it will present
clinical data from the company-sponsored phase 1 dose escalation study
on its BTK inhibitor, ARQ 531, for the treatment of relapsed or
refractory B-cell lymphoid malignancies in a poster presentation at the
24th Congress of European Hematology Association (EHA), held
from June 13-16, 2019 in Amsterdam.
May 30, 2019 07:00 am ET
ArQule to Present at the Jefferies 2019 Healthcare Conference on June 6, 2019
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief
Executive Officer, Peter Lawrence, President and Chief Operating
Officer, and Marc Schegerin, Chief Financial Officer and Head of
Strategy, will present at the Jefferies 2019 Healthcare Conference on
June 6, 2019 at 11:30 a.m. ET at the Grand Hyatt in New York City.
May 15, 2019 07:00 am ET
ArQule to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019
ArQule, Inc. (Nasdaq: ARQL) today announced that Dr. Marc Schegerin,
Chief Financial Officer and Head of Strategy, will present at the 20th
Annual B. Riley FBR Institutional Investor Conference on May 22, 2019 at
9:30 a.m. PT at the Beverly Hilton in Beverly Hills, CA.
May 14, 2019 07:00 am ET
ArQule to Present at the 2019 RBC Capital Markets Global Healthcare Conference on May 21, 2019
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief
Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and
Head of Research and Development, will present at the 2019 RBC Capital
Markets Global Healthcare Conference on May 21, 2019 at 3:35 p.m. ET at
the InterContinental New York Barclay in New York City.
May 08, 2019 07:00 am ET
ArQule to Present at the Bank of America Merrill Lynch 2019 Health Care Conference on May 15, 2019
ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence,
President and Chief Operating Officer, and Dr. Marc Schegerin, Chief
Financial Officer and Head of Strategy, will present at the Bank of
America Merrill Lynch 2019 Health Care Conference on May 15, 2019 at
3:15 p.m. PT at the Encore Hotel in Las Vegas, NV.
May 01, 2019 07:00 am ET
ArQule Reports First Quarter 2019 Financial Results
ArQule,
Inc. (Nasdaq: ARQL) today announced its financial results for the first
quarter, 2019.
Apr 30, 2019 04:01 pm ET
Sinovant Sciences Announces Approval of Derazantinib’s Clinical Trial Application by the China National Medical Products Administration
ArQule, Inc.’s (Nasdaq: ARQL) partner, Sinovant Sciences, announced that
its Clinical Trial Application (CTA) for derazantinib has been accepted
by the Center for Drug Evaluation at the China National Medical Products
Administration (NMPA), enabling the initiation of a registrational
clinical trial in patients with second-line intrahepatic
cholangiocarcinoma (iCCA) in the second half of 2019.
Apr 17, 2019 04:01 pm ET
ArQule to Report First Quarter 2019 Financial Results on May 1, 2019
ArQule,
Inc. (Nasdaq: ARQL) today announced it will report financial results for
the first quarter of 2019 before the market opens on Wednesday, May 1,
2019. The Company will hold a conference call and webcast on the same
day at 9:00 a.m. ET to discuss these results and provide a general
business update.
Apr 10, 2019 07:20 am ET
Analysis: Positioning to Benefit within Autodesk, Pebblebrook Hotel Trust, Boston Properties, FORTERRA INC, ArQule, and MongoDB — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Autodesk, Inc. (NASDAQ:ADSK), Pebblebrook Hotel Trust (NYSE:PEB), Boston...
Apr 02, 2019 07:00 am ET
ArQule to Present at 18th Annual Needham Healthcare Conference on April 9, 2019
ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence,
President and Chief Operating Officer, and Dr. Marc Schegerin, Chief
Financial Officer and Head of Strategy, will present at the 18th Annual
Needham Healthcare Conference on April 9, 2019 at 10:00 a.m. ET at the
Westin New York Grand Central in New York City.
Mar 15, 2019 07:00 am ET
ArQule Announces Management Team Changes
ArQule, Inc. (Nasdaq: ARQL) today announced that Robert Weiskopf, Senior
Vice President, Chief Financial Officer and Treasurer, has decided to
retire effective March 29 of this year. In conjunction with Mr.
Weiskopf’s departure, ArQule is naming Marc Schegerin, MD as Chief
Financial Officer and Head of Strategy, effective as of Mr. Weiskopf’s
retirement. Dr. Schegerin joined ArQule in May 2018 and most recently
served as Senior Vice President, Head of Strategy, Finance and
Communication.
Mar 13, 2019 07:00 am ET
ArQule to Present at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019
ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence,
President and Chief Operating Officer, and Brian Schwartz, MD, Chief
Medical Officer and Head of Research and Development, of ArQule will
present at Oppenheimer’s 29th Annual Healthcare Conference on March 20,
2019 at 10:20 a.m. ET at the Westin New York Grand Central in New York
City.
Mar 11, 2019 07:00 am ET
ArQule to Participate in the 31st Annual ROTH Conference on March 17-19, 2019
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief
Executive Officer, and Marc Schegerin, Senior Vice President and Head of
Strategy, Finance and Communication, will participate in the 31st Annual
ROTH Conference on March 17-19, 2019 in Dana Point, California.
Mar 07, 2019 07:00 am ET
ArQule Reports Fourth Quarter and Full Year 2018 Financial Results
ArQule,
Inc. (Nasdaq: ARQL) today announced its financial results for the fourth
quarter and full year of 2018.
Feb 26, 2019 07:45 am ET
Factors of Influence in 2019, Key Indicators and Opportunity within Conagra Brands, Pieris Pharmaceuticals, ArQule, MoneyGram International, Internap, and TIM Participacoes S.A — New Research Emphasiz
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Conagra Brands Inc. (NYSE:CAG), Pieris Pharmaceuticals, Inc....
Feb 25, 2019 07:00 am ET
ArQule Announces Publication of Clinical Data with Miransertib in Proteus Syndrome
ArQule, Inc. (Nasdaq:ARQL), today announced the publication of clinical
pharmacodynamic, safety and efficacy data in patients with Proteus
syndrome. These data, together with data already presented at ASHG last
year, support miransertib’s further development as a potential first
systemic treatment for patients suffering from overgrowth diseases, such
as Proteus syndrome. The study, published in the American Journal of
Human Genetics, and led by the National Institutes of Health (NIH),
demonstrated good target engagement, tolerability and reducti
Feb 21, 2019 07:00 am ET
ArQule to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief
Executive Officer, and Brian Schwartz, M.D., Chief Medical Officer and
Head of Research and Development, of ArQule will present at the 8th
Annual Leerink Partners Global Healthcare Conference on February 28,
2019, at 11:30 a.m. ET at the Lotte New York Palace in New York City.
Feb 21, 2019 07:00 am ET
ArQule to Report Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019
ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial
results for the fourth quarter and full year of 2018 before the market
opens on Thursday, March 7, 2019. The Company will hold a conference
call and webcast on the same day at 9:00 a.m. ET to discuss these
results and provide a general business update.
Jan 24, 2019 07:00 am ET
Basilea Announces Collaboration to Study Derazantinib and Atezolizumab (Tecentriq®) in Urothelial Cancer
ArQule, Inc.’s (Nasdaq: ARQL) partner, Basilea Pharmaceutica Ltd. (SIX:
BSLN), announced today that it entered into a collaboration with Roche
(SIX: RO, ROG) to explore a combination of derazantinib (BAL087) and
Roche’s PD-L1-blocking immune-checkpoint inhibitor, atezolizumab
(Tecentriq®), in patients with urothelial cancer. Basilea
expects to start a biomarker-driven multi-cohort phase 1/2 study in
mid-2019.
Jan 09, 2019 07:00 am ET
Basilea Announces Positive Interim Results from Registrational Phase 2 Study with Oncology Drug Candidate Derazantinib in Intrahepatic Cholangiocarcinoma (iCCA)
ArQule, Inc.’s (Nasdaq: ARQL) partner, Basilea Pharmaceutica Ltd. (SIX:
BSLN), today announced results from the interim analysis of the
registrational Phase 2 study with the orally administered pan-fibroblast
growth factor receptor (FGFR) kinase inhibitor derazantinib (BAL087).
The analysis showed promising activity in patients with FGFR2 gene
fusion-expressing intrahepatic cholangiocarcinoma (iCCA) and also
confirmed the safety profile and tolerability of the drug candidate
observed in previous clinical studies.
Dec 26, 2018 07:25 am ET
Detailed Research: Economic Perspectives on Canopy Growth, ArQule, MoneyGram International, Teradata, Clovis Oncology, and Axovant Sciences — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Canopy Growth Corporation (NYSE:CGC), ArQule, Inc. (NASDAQ:ARQL),...
Dec 19, 2018 07:00 am ET
ArQule Added to the NASDAQ Biotechnology Index
ArQule, Inc. (Nasdaq: ARQL) today announced that it has been selected
for inclusion in the NASDAQ Biotechnology Index (Nasdaq: NBI), which
will become effective prior to market open on Monday, December 24, 2018.
Dec 03, 2018 07:00 am ET
ArQule Announces Clinical Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2018 ASH Annual Meeting
ArQule, Inc. (Nasdaq: ARQL) yesterday presented preliminary results from
the Company’s Phase 1 dose escalation study for ARQ 531, an orally
bioavailable, potent and reversible inhibitor of both wild type and
C481S-mutant Bruton’s tyrosine kinase (BTK) in patients with relapsed or
refractory hematologic malignancies at the 2018 American Society of
Hematology (ASH) Annual Meeting in San Diego.
Dec 01, 2018 06:35 am ET
ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 2018 American Society of Hematology (ASH) Annual Meeting
ArQule, Inc. (Nasdaq:ARQL) today announced that it will present clinical
data on the company’s BTK inhibitor, ARQ 531, in a poster presentation
at the 60th American Society of Hematology (ASH) Annual
Meeting and Exposition to be held from December 1 to 4, 2018 in San
Diego.
Nov 29, 2018 07:35 am ET
Recent Analysis Shows HudBay Minerals, Meridian Bioscience, ArQule, Mesoblast, Concho Resources, and Liberty Global Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of HudBay Minerals Inc (NYSE:HBM), Meridian Bioscience Inc. (NASDAQ:VIVO),...
Nov 29, 2018 07:00 am ET
ArQule to Host Analyst Call Highlighting Clinical Progress from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies
ArQule, Inc. (Nasdaq: ARQL) today announced that it will host a call to
discuss the updated safety, PK, biomarker and anti-tumor activity data
from the company’s Phase 1 dose escalation study in patients with
relapsed or refractory hematologic malignancies (ARQ 531-101) that are
being presented in a poster presentation at the 60th American
Society of Hematology (ASH) Annual Meeting and Exposition on December 3,
2018 in San Diego.
Nov 19, 2018 07:00 am ET
ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 2018 American Society of Hematology (ASH) Annual Meeting
ArQule, Inc. (Nasdaq:ARQL) today announced that it will present clinical
data on the company’s BTK inhibitor, ARQ 531, in a poster presentation
at the 60th American Society of Hematology (ASH) Annual
Meeting and Exposition to be held from December 1 to 4, 2018 in San
Diego.
Nov 16, 2018 04:01 pm ET
ArQule Presents Clinical and Preclinical Data for ARQ 751 at the 30th EORTC/AACR/NCI Symposium
ArQule, Inc. (Nasdaq: ARQL) today announced the presentation of clinical
and preclinical data on ARQ 751 in three poster presentations at the
30th EORTC/AACR/NCI Symposium held from November 13 to 16, 2018 in
Dublin, Ireland. The data presented highlight clinical data from ARQ
751-101, a Phase 1 study in adult patients with refractory and/or
metastatic tumors that harbor AKT, PI3K or PTEN genetic alterations, and
preclinical data on ARQ 751 in combination with other agents.
Nov 14, 2018 07:00 am ET
ArQule to Present at the 30th Annual Piper Jaffray Healthcare Conference on November 28, 2018
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief
Executive Officer, and Marc Schegerin, Senior Vice President, Head of
Strategy, Finance, and Communication will present at the 30th Annual
Piper Jaffray Healthcare Conference on November 28, 2018, at 1:50pm ET
at the Lotte New York Palace in New York City.
Nov 08, 2018 07:00 am ET
ArQule to Present Clinical and Preclinical Data for ARQ 751 at the 30th EORTC/AACR/NCI Symposium
ArQule, Inc. (Nasdaq: ARQL) today announced that it will be presenting
clinical and preclinical data on the company’s next generation AKT
inhibitor, ARQ 751, in three poster presentations at the 30th
EORTC/AACR/NCI Symposium to be held from November 13 to 16, 2018 in
Dublin, Ireland.
Oct 31, 2018 07:00 am ET
ArQule Reports Third Quarter 2018 Financial Results
ArQule,
Inc. (Nasdaq: ARQL) today announced its financial results for the third
quarter of 2018.
Oct 19, 2018 08:40 am ET
New Research Coverage Highlights TIER REIT, Meridian Bioscience, ArQule, Greenlight Capital Re, ADT, and Turquoise Hill Resources — Consolidated Revenues, Company Growth, and Expectations for 2018
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of TIER REIT, Inc. (NYSE:TIER), Meridian Bioscience Inc. (NASDAQ:VIVO),...
Oct 19, 2018 07:00 am ET
ArQule Presents Orphan Disease Clinical Data at the American Society of Human Genetics (ASHG) 2018 Annual Meeting for Its pan-AKT Inhibitor, Miransertib (ARQ 092)
ArQule, Inc. (Nasdaq:ARQL) today announced the presentation of
preliminary clinical data on miransertib (ARQ 092) in three poster
presentations at the American Society of Human Genetics (ASHG) 2018
Annual Meeting held from October 16 to 20, 2018 in San Diego. The data
presented relate to patients affected by either Proteus syndrome or PROS
who have been receiving miransertib as part of a clinical trial or in a
compassionate use setting.
Oct 17, 2018 07:00 am ET
ArQule to Report Third Quarter 2018 Financial Results on October 31, 2018
ArQule,
Inc. (Nasdaq: ARQL) today announced it will report financial results for
the third quarter of 2018 before the market opens on Wednesday, October
31, 2018. The Company will hold a conference call and webcast on the
same day at 9:00 a.m. ET to discuss these results and provide a general
business update.
Oct 04, 2018 04:01 pm ET
ArQule to Present Clinical Update for Miransertib in Rare Disease at the American Society of Human Genetics (ASHG) 2018 Annual Meeting
ArQule, Inc. (Nasdaq: ARQL) today announced that it will be presenting
clinical data on the company’s lead AKT inhibitor, miransertib (ARQ
092), in three poster presentations at the American Society of Human
Genetics (ASHG) 2018 Annual Meeting to be held from October 16 to 20,
2018 in San Diego, CA.
Sep 24, 2018 07:00 am ET
ArQule to Present at the Cantor Global Healthcare Conference on October 1, 2018
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief
Executive Officer, and Marc Schegerin, Senior Vice President, Strategy,
Communication and Finance, will present at the Cantor Global Healthcare
Conference on October 1, 2018, at 2:55pm ET at the InterContinental New
York Barclay Hotel in New York City.
Sep 24, 2018 07:00 am ET
ArQule to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology on October 2, 2018
ArQule, Inc. (Nasdaq:ARQL) today announced that Peter Lawrence,
President and Chief Operating Officer, Dr. Brian Schwartz, Chief Medical
Officer and Head of Research and Development, and Marc Schegerin, Senior
Vice President, Strategy, Communication and Finance, will present at the
Leerink Partners Roundtable Series on October 2, 2018, at 8:00am ET at
the Lotte New York Palace in New York City.
Sep 13, 2018 07:00 am ET
Miransertib (ARQ 092) Granted Fast Track Designation for the Treatment of PIK3CA-Related Overgrowth Spectrum (PROS)
ArQule, Inc. (Nasdaq: ARQL) today announced that the U.S. Food and Drug
Administration (FDA) has granted Fast Track Designation to miransertib
(ARQ 092) for the treatment of PIK3CA-Related Overgrowth Spectrum
(PROS), a group of related, ultra-rare genetic disorders characterized
by excessive tissue growth in various parts of the body. The FDA’s Fast
Track program aims to expedite the development and review of drugs which
treat serious or life-threatening conditions and have demonstrated the
potential to address unmet clinical needs.
Aug 30, 2018 04:01 pm ET
ArQule to Participate in Citi’s 13th Annual Biotech Conference on September 6, 2018
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, CEO, Peter
Lawrence, President and COO, Brian Schwartz, CMO and Head of R&D and
Marc Schegerin, Senior Vice President and Head of Strategy, Finance and
Communication, will participate in Citi’s 13th Annual Biotech Conference
on September 6, 2018, at the Four Seasons Hotel in Boston, MA.
Aug 30, 2018 04:01 pm ET
ArQule to Participate in the Annual B. Riley FBR Healthcare Conference on September 4, 2018
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, CEO, and
Dr. Brian Schwartz, CMO and Head of Research and Development, will
participate in investor meetings and scientific panel discussions at the
B. Riley FBR Healthcare Conference on September 4, 2018, at the New York
Marriott East Side Hotel in New York City.
Aug 29, 2018 04:01 pm ET
ArQule to Present at the 20th Annual Global Investment Conference on September 5, 2018
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief
Executive Officer, and Marc Schegerin, Senior Vice President, Strategy,
Communication and Finance, will present at the 20th Annual
Rodman & Renshaw Global Investment Conference, sponsored by H.C.
Wainwright & Co., LLC, on September 5, 2018, at 12:05pm ET at the St.
Regis New York Hotel in New York City.
Aug 21, 2018 07:40 am ET
Analysis: Positioning to Benefit within PagSeguro Digital, ChannelAdvisor, Transocean, Arcos Dorados, Precision Drilling, and ArQule — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PagSeguro Digital Ltd. (NYSE:PAGS), ChannelAdvisor Corporation...
Aug 13, 2018 04:01 pm ET
ArQule Announces Publication of Preclinical Data for ARQ 531, a Reversible Inhibitor of Both Wild Type and Mutant BTK
ArQule, Inc. (Nasdaq:ARQL), today announced the publication of
preclinical study data for ARQ 531, the Company’s rationally-designed,
reversible inhibitor of both wild type and C481S-mutant Bruton’s
tyrosine kinase (BTK). The studies, published in Cancer Discovery,
were conducted in collaboration with researchers at The Ohio State
University. Data from these studies demonstrated efficacy in in vitro
and in vivo hematologic malignancy models that recapitulate the
most common mechanisms of resistance to irreversible BTK inhibi
Aug 01, 2018 07:00 am ET
ArQule Reports Second Quarter 2018 Financial Results
ArQule,
Inc. (Nasdaq: ARQL) today announced its financial results for the second
quarter of 2018.
Jul 18, 2018 06:18 pm ET
ArQule to Report Second Quarter 2018 Financial Results on August 1, 2018
ArQule,
Inc. (Nasdaq: ARQL) today announced it will report financial results for
the second quarter of 2018 before the market opens on Wednesday, August
1, 2018. The Company will hold a conference call and webcast on the same
day at 9:00 a.m. ET to discuss these results and provide a general
business update.
Jul 13, 2018 04:01 pm ET
ArQule Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
ArQule, Inc. (Nasdaq: ARQL) today announced the closing of its
previously announced underwritten public offering of common stock,
including the exercise in full by the underwriters of their option to
purchase an additional 1,650,000 shares at the public offering price of
$5.50 per share. The exercise of the option to purchase additional
shares brought the total number of shares of common stock sold by ArQule
to 12,650,000 shares and increased the gross proceeds raised in the
offering, before deducting underwriting discounts and commissions and
Jul 11, 2018 07:00 am ET
ArQule Announces Pricing of $60.5 Million Public Offering of Common Stock
ArQule, Inc. (Nasdaq: ARQL) today announced the pricing of an
underwritten public offering of 11 million shares of its common stock at
a price to the public of $5.50 per share. ArQule has granted the
underwriters a 30-day option to purchase up to an additional 1.65
million shares of its common stock. The offering is expected to close on
or about July 13, 2018, subject to satisfaction of customary closing
conditions. The gross proceeds to ArQule from the offering, excluding
any exercise by the underwriters of their 30-day option to purchase
Jul 10, 2018 04:12 pm ET
ArQule Announces Commencement of Proposed Public Offering of Common Stock
ArQule, Inc. (Nasdaq: ARQL) today announced that it has commenced an
underwritten public offering, subject to market and other conditions, to
issue and sell shares of its common stock. In connection with the
offering, ArQule expects to grant the underwriters a 30-day option to
purchase up to an additional 15% of the shares of its common stock
offered in the public offering. There can be no assurances as to whether
or when the offering may be completed, or as to the actual size or terms
of the offering. All of the shares in the offering are to be
Jun 25, 2018 07:00 am ET
ArQule Added to the Russell 2000® Index
ArQule, Inc. (Nasdaq: ARQL) today announced that it has been added to
the Russell 2000® Index, a subset of the
Russell 3000® Index, effective as of market closing on June
22, 2018, at the conclusion of the annual Russell US Index
reconstitution.
Jun 15, 2018 07:00 am ET
ArQule Presents Results from Ongoing Phase 1 Dose Escalation Study of its Reversible BTK Inhibitor, ARQ 531
ArQule, Inc. (Nasdaq:ARQL) today is presenting preliminary results from
the Company’s Phase 1 dose escalation study for ARQ 531, an orally
bioavailable, potent and reversible inhibitor of both wild type and
C481S-mutant Bruton’s tyrosine kinase (BTK) in patients with relapsed or
refractory hematologic malignancies at the 23rd Congress of European
Hematological Association (EHA) in Stockholm, Sweden.
Jun 14, 2018 07:00 am ET
ArQule to Present at The JMP Securities Life Sciences Conference on June 21, 2018
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief
Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and
Head of Research and Development, will present at The JMP Securities
Life Sciences Conference on June 21, 2018, at 10:30am EDT at the
St. Regis in New York.
Jun 11, 2018 08:00 am ET
The Race to Treat Cancer, ArQule Inc. Continues Progress Across All Pipeline Assets
Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on ArQule Inc. (NASDAQ: ARQL), a bio-pharmaceutical company engaged in the research...
Jun 08, 2018 08:00 am ET
Research Report Identifies Qudian Inc., ICICI Bank, Mobile TeleSystems OJSC, ArQule, Alibaba Group Holding, and Arcos Dorados with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Qudian Inc. (NYSE:QD), ICICI Bank Limited (NYSE:IBN), Mobile TeleSystems...
Jun 07, 2018 07:00 am ET
ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 23rd Congress of the European Hematology Association (EHA)
ArQule, Inc. (Nasdaq: ARQL) today announced clinical data from the
company-sponsored ARQ 531-101 Phase 1 dose escalation study in subjects
with relapsed or refractory hematologic malignancies will be presented
on June 15, 2018 at the EHA Congress in Stockholm, Sweden. ARQ 531 is an
orally bioavailable, potent and reversible inhibitor of both wild type
and C481S-mutant Bruton’s tyrosine kinase (BTK).
May 31, 2018 07:00 am ET
ArQule to Present at the Jefferies 2018 Healthcare Conference on June 7, 2018
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief
Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and
Head of Research and Development, will present at the Jefferies 2018
Healthcare Conference on June 7, 2018, at 3:00 p.m. ET at the Grand
Hyatt, New York, New York.
May 24, 2018 07:00 am ET
ArQule Strengthens Executive Team with Two Key Appointments
ArQule, Inc. (NASDAQ: ARQL) today announced two strategic additions to
its executive team, appointing Dr. Marc Schegerin as senior vice
president, corporate strategy, communication and finance, and Dr.
Shirish Hirani as senior vice president, program management and product
planning.
May 07, 2018 07:00 am ET
ArQule Reports First Quarter 2018 Financial Results
ArQule,
Inc. (Nasdaq: ARQL) today announced its financial results for the first
quarter of 2018.
Apr 23, 2018 04:35 pm ET
ArQule to Report First Quarter 2018 Financial Results on May 7, 2018
ArQule,
Inc. (Nasdaq: ARQL) today announced it will report financial results for
the first quarter of 2018 before the market opens on Monday, May 7,
2018. The Company will hold a conference call and webcast on the same
day at 9:00 a.m. ET to discuss these results and provide a general
business update.
Apr 17, 2018 07:00 am ET
ArQule and Basilea Enter into Exclusive License Agreement for Derazantinib in the US, EU, Japan and Rest of World Excluding Greater China
ArQule, Inc. (NASDAQ:ARQL) today announced that it has entered into an
exclusive license agreement with Basilea Pharmaceutica International
Limited (Basilea, SIX: BSLN) to develop and commercialize
derazantinib, a pan-FGFR (fibroblast growth factor receptor) inhibitor
in the US, EU, Japan and rest of the world excluding the People’s
Republic of China, Hong Kong, Macau and Taiwan, where Sinovant Sciences
Ltd., a Roivant Sciences Ltd. subsidiary, has rights to develop and
exclusively commercialize the drug.
Mar 27, 2018 07:50 am ET
Recent Analysis Shows Energy Fuels, Vipshop, Tenaris S.A, ArQule, Teekay Offshore Partners, and Chicago Bridge & Iron Company N.V Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Energy Fuels Inc (NYSE:UUUU), Vipshop Holdings...
Mar 20, 2018 07:00 am ET
ArQule to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief
Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and
Head of Research and Development, will present at the 17th
Annual Needham Healthcare Conference on March 27th, 2018, at
3:30 p.m. ET at the Westin Grand Central Hotel in New York, New York.
Mar 15, 2018 07:00 am ET
ArQule to Present Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting
ArQule, Inc. (Nasdaq: ARQL) today announced that pre-clinical and
clinical data on the company’s pipeline of drug candidates will be
presented at the 2018 AACR Annual Meeting taking place in Chicago from
April 14-April 18. Data will be presented in one oral and nine poster
sessions on trials conducted by ArQule and its collaborators for BTK
inhibitor, ARQ 531, AKT inhibitors, miransertib and ARQ 751, as well as
FGFR inhibitor, derazantinib.
Mar 05, 2018 07:00 am ET
ArQule Reports Fourth Quarter and Full Year 2017 Financial Results
ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for
the fourth quarter and full year of 2017.
Mar 05, 2018 06:50 am ET
ArQule to Present at the 30th Annual Roth Conference on March 12, 2018
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief
Executive Officer, will present at the 30th Annual Roth
Conference on March 12th, 2018, at 5:00 p.m. PT at the
Ritz-Carlton in Dana Point, California.
Feb 20, 2018 07:00 am ET
ArQule To Report Fourth Quarter 2017 Financial Results On March 5, 2018
ArQule,
Inc. (Nasdaq: ARQL) today announced it will report financial results for
the fourth quarter 2017 before the market opens on Monday, March 5,
2018. The Company will hold a conference call and webcast on the same
day at 9:00 a.m. ET to discuss these results and provide a general
business update.
Feb 08, 2018 07:00 am ET
ArQule to Present at The Leerink Partners 7th Annual Global Healthcare Conference on February 15, 2018
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief
Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and
Head of Research and Development, will present at the Leerink Partners 7th
Annual Global Healthcare Conference on February 15th, 2018,
at 9:00 a.m. ET at the Lotte New York Palace in New York, New York.
Feb 07, 2018 07:00 am ET
Roivant Sciences and ArQule Enter into License Agreement for Derazantinib in China
Roivant Sciences and ArQule, Inc. (NASDAQ: ARQL) today announced the
initiation of a collaboration to pursue the development of derazantinib,
a pan-FGFR (fibroblast growth factor receptor) inhibitor, in Greater
China. As part of the collaboration, ArQule has granted a Roivant
subsidiary an exclusive license to develop and commercialize
derazantinib in the People’s Republic of China, Hong Kong, Macau, and
Taiwan. Deal terms include an upfront payment to ArQule of $3 million
and an additional $2.5 million development milestone within the first
Nov 21, 2017 07:00 am ET
ArQule Announces Dosing in a Registrational Trial of FGFR Inhibitor, Derazantinib, for Treatment of Intrahepatic Cholangiocarcinoma
ArQule, Inc. (Nasdaq: ARQL) today announced dosing of the initial
patients in a registrational trial with its FGFR inhibitor, derazantinib
(ARQ 087) in FGFR2 fusion driven second-line intrahepatic
Cholangiocarcinoma (iCCA). The trial is planned to enroll up to 100 iCCA
patients and provides an opportunity for a conditional approval as part
of a fast-to-market strategy. Derazantinib is a multi-kinase inhibitor
designed to preferentially inhibit the fibroblast growth factor receptor
(FGFR) family.
Nov 09, 2017 07:00 am ET
ArQule Reports Third Quarter 2017 Financial Results
ArQule,
Inc. (Nasdaq: ARQL) today announced its financial results for the third
quarter of 2017.
Nov 08, 2017 07:00 am ET
ArQule Announces $9.5 Million Private Placement of Preferred Stock
ArQule, Inc. (NASDAQ: ARQL) today announced the closing of a private
placement with institutional investors led by The Pontifax Group
pursuant to which the Company raised gross proceeds of $9.5 million
through the sale of approximately 8,370 shares of series A convertible
preferred stock (Series A Preferred) and warrants covering 2,260 shares
of Series A Preferred (Warrants). Each share of Series A Preferred
together with the associated Warrant is priced at $1,135 and will
automatically convert into 1,000 shares of common stock upon the
a
Nov 01, 2017 07:00 am ET
FDA Grants Rare Pediatric Disease Designation to ArQule’s Miransertib (ARQ 092) for the Treatment of Proteus Syndrome
ArQule, Inc. (Nasdaq: ARQL) today announced that the U.S. Food and Drug
Administration (FDA) has granted Rare Pediatric Disease Designation to
miransertib (ARQ 092) for the treatment of Proteus syndrome. Under the
FDA’s rare pediatric disease priority review voucher program, the
sponsor may be eligible for a voucher that can be used to obtain
priority review for a subsequent human drug application if it meets
relevant statutory requirements associated with the program, including
FDA approval of the drug in this indication. The FDA previously gra
Oct 26, 2017 07:00 am ET
ArQule To Report Third Quarter 2017 Financial Results On November 9, 2017
ArQule,
Inc. (Nasdaq: ARQL) today announced it will report financial results for
the third quarter 2017 before the market opens on Thursday, November 9,
2017. The Company will hold a conference call and webcast on the same
day at 9:00 a.m. ET to discuss these results and provide a general
business update.
Oct 16, 2017 07:00 am ET
ArQule Announces $15.7 Million Private Placement of Common Stock
ArQule, Inc. (NASDAQ: ARQL) today announced the closing of a private
placement with certain institutional investors, with leading
participation by BVF Partners L.P., pursuant to which the Company raised
gross proceeds of approximately $15.7 million through the sale of
13,938,651 shares of common stock and 3,123,674 warrants. ArQule
estimates the net proceeds from this offering will be approximately
$15.5 million. The warrants have an exercise price of $1.75 per share,
will be exercisable immediately and expire four years after the date of
Jun 26, 2017 12:22 pm ET
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating ArQule, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK, June 26, 2017 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of ArQule, Inc. (NASDAQ: ARQL).
Jan 05, 2017 09:00 am ET
The Life Sciences Report Announces 19 Companies Selected for the 2017 Small-Cap Biotech Watchlist
Now in its fifth year, the 2017 Life Sciences Report Biotech Watchlist includes nineteen small-cap biotech companies selected by top analysts in the field, and will be presented at the Biotech Showcase in San Francisco on January 11. Included in...
Jul 20, 2016 07:00 am ET
ArQule To Report Second Quarter 2016 Financial Results On August 3, 2016
BURLINGTON, Mass., July 20, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced it will report financial results for the second quarter 2016 before the market opens on Wednesday, August 3, 2016. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business update. ...
Jul 18, 2016 04:00 pm ET
ArQule Presents Preclinical Data for ARQ 531, a Proprietary Reversible Inhibitor of Wild Type and Mutant BTK, at the 2016 Pan Pacific Lymphoma Conference
Data supports further preclinical and clinical research in BTK sensitive and ibrutinib resistant malignancies...
Jul 05, 2016 07:00 am ET
ArQule to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on July 12, 2016
BURLINGTON, Mass., July 05, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on July 12th, 2016, at 2:30 p.m. ET at Le Parker Meridien in New York, New York....
Jun 30, 2016 07:00 am ET
ArQule Presents Preliminary Clinical Data for ARQ 087 Demonstrating Evidence of Anticancer Activity in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer
75% disease control rate, including a 25% objective response rate, was observed in 12 evaluable patients harboring FGFR2 genetic alterations...
Jun 23, 2016 07:00 am ET
ArQule to Present Preliminary Phase 1/2 Data for FGFR Inhibitor, ARQ 087, in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer
BURLINGTON, Mass., June 23, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that preliminary data from the ongoing phase 2 portion of a phase 1/2 trial in intrahepatic cholangiocarcinoma (iCCA) with our proprietary fibroblast growth factor receptor (FGFR) inhibitor, ARQ 087, will be presented on June 30, 2016 at the ESMO 18th World Congress on Gastrointestinal Cancer in Barcelona, Spain. This is a biomarker driven trial designed to enroll at least 20 patients in iCCA with FGFR2 genetic alterations. The company has been granted orphan drug designation by the U.S. Food an...
May 04, 2016 07:00 am ET
ArQule Reports First Quarter 2016 Financial Results
Conference call scheduled today at 9:00 a.m. ET...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.